文献速递前列腺癌

NEAR试验:新辅助阿帕他胺单药治疗联合根治性前列腺切除术治疗中高危前列腺癌的单臂II期试验

NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-01-28

NEAR试验为单臂II期研究,纳入30例D'Amico中高危前列腺腺癌患者,接受阿帕他胺240 mg每日一次共12周后行根治性前列腺切除术±淋巴结清扫。主要终点病理完全缓解(pCR)未达到,25例按方案完成治疗者中无pCR,中位肿瘤负荷减少41.7%(IQR 33.3%-60.0%),18/25例达生化反应。低雄激素受体活性或PAM50基底型肿瘤可能与生化无反应相关。

要点

  • 12周新辅助阿帕他胺单药后根治性前列腺切除术未观察到病理完全缓解(pCR)。
  • 25例按方案完成治疗者中18例达生化反应,中位肿瘤负荷减少41.7%(IQR 33.3%-60.0%)。
  • 常见不良事件为皮肤干燥(53.3%)、疲乏(33.3%)和皮疹(30.0%),无重大围手术期并发症。

核心结论

  • 根治性前列腺切除术前12周新辅助阿帕他胺未达到pCR的主要终点。
  • 低雄激素受体活性或PAM50基底亚型肿瘤对阿帕他胺的反应可能降低。

研究设计与样本

  • NEAR试验为单臂II期研究(NCT03124433),评估新辅助阿帕他胺单药联合根治性前列腺切除术治疗D'Amico中高危前列腺癌。
  • 2017年至2019年共招募30例组织学证实的前列腺腺癌患者,其中高危20例、中危10例;25例按方案完成治疗。
  • 患者接受阿帕他胺240 mg每日一次共12周,随后行根治性前列腺切除术±淋巴结清扫;主要终点为病理完全缓解(pCR)率。

主要发现

  • 试验中未观察到任何pCR;中位肿瘤负荷减少41.7%(IQR 33.3%-60.0%)。
  • 25例按方案完成治疗者中18例达生化反应(4例未在第24周达到PSA<0.03 ng/mL,3例随后出现PSA复发)。
  • 最常见不良事件为皮肤干燥(N=16;53.3%)、疲乏(N=10;33.3%)和皮疹(N=9;30.0%),无重大围手术期并发症。
  • 低雄激素受体活性肿瘤和PAM50基底状态与生化无反应者相关,但这些分子表型与病理反应无关。

关键数值与推荐

  • 生化反应定义为从开始阿帕他胺起第24周时PSA<0.03 ng/mL且随后无PSA复发。
  • pCR率主要终点未达到(原文未报告具体pCR率数值)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Treatment efficacy of androgen deprivation therapy with radical prostatectomy for intermediate- to high-risk prostate cancer is less well-studied. The NEAR trial is a single-arm, phase II investigation of neoadjuvant apalutamide monotherapy and radical prostatectomy (RP) in the treatment of D'Amico intermediate- and high-risk prostate cancer (NCT03124433). MATERIALS AND METHODS: Patients with histologically-proven, D'Amico intermediate- to high-risk prostate adenocarcinoma received apalutamide 240 mg once-daily for 12 weeks followed by RP + /-lymphadenectomy. Primary outcome was pathological complete response (pCR) rate. Secondary outcomes included rate of biochemical response (defined by PSA < 0.03 ng/mL at week 24 from starting apalutamide without subsequent PSA relapse), treatment-related adverse events, and RP complication rates. Correlative biomarker analyses were performed to examine for molecular predictors of treatment responses. RESULTS: From 2017 to 2019, 30 patients were recruited, of which 20 and 10 were high and intermediate risk, respectively; 25 completed treatment as per-protocol. We did not observe any pCR on trial; median reduction of cancer burden was 41.7% (IQR: 33.3%-60.0%). 18 out of 25 patients were classified as having a biochemical response (4 did not achieve PSA of <0.03 ng/mL at week 24 and 3 developed PSA relapse subsequently). Dry skin (N = 16; 53.3%), fatigue (N = 10; 33.3%) and skin rash (N = 9; 30.0%) were the most common adverse events, and there was no major peri-operative complication. We observed an association between tumours of low androgen receptor activity and PAM50 basal status with biochemical non-responders, albeit these molecular phenotypes were not associated with pathological response. CONCLUSIONS: A 12-week course of neoadjuvant apalutamide prior to RP did not meet the primary endpoint of pCR in this trial. Tumours with low androgen receptor activity or of the PAM50 basal subtype may have a reduced response to apalutamide.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Lee LS, Sim AYL, Ong CW, et al. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 35091711. doi:10.1038/s41391-022-00496-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。